Early diagnosis and prompt treatment are the goals of modern therapy, but there are no randomized controlled trials to guide treatment and the published literature contains a high ratio of reviews to original data. Much of that data comes from case reports and often small, retrospective series with no clearly defined treatment criteria. 

Methods A study group of the European Society for Trauma and Emergency Surgery (ESTES) was formed in 2013 with the aim of developing guidelines for the management of AMI. A comprehensive literature search was performed using the Medical Subject Heading (MeSH)
thesaurus keywords “mesenteric ischaemia”, “bowel ischaemia” and “bowel infarction”. The bibliographies of relevant articles were screened for additional publications. After an initial systematic review of the literature by the whole group, a steering group formulated questions using a modified Delphi process. The evidence was then reviewed to answer these questions, and recommendations formulated and agreed by the whole group.

Results The resultant recommendations are presented in this paper.

Conclusions The aim of these guidelines is to provide recommendations for practice that will lead to improved outcomes for patients.

Keywords Acute mesenteric ischaemia · Diagnosis · Clinical management · Guidelines

Introduction

AMI accounts for about 1:1000 acute hospital admissions in Europe and the USA [1]. In Japan, where the incidence of vascular disease is lower, this figure has been estimated at 1:10,000 [2]. The incidence appears to be increasing due to an ageing general population with increasing prevalence of comorbidities. This pre-existing disease worsens the prognosis of intestinal necrosis [3].

The diagnosis of AMI is difficult and it will often go unrecognized as a cause of death. A population-based study from a national general practitioner database in the UK estimated the overall incidence of AMI at 0.63 per 100,000 person years [4], while a population-based study in Sweden with an 87 % autopsy rate estimated the incidence more than twenty times higher at 12.9 per 100,000 person years [5]. Sixty-five percent of acute superior mesenteric artery occlusions were diagnosed at autopsy. The incidence increases exponentially with age and there appears to be an equal incidence in men and women after adjusting for age and gender in the population [5]. While the mean age is around 70 years in most studies, several report cases in their 20s [2, 6–9].

Four different aetiological forms of AMI have been identified: arterial embolism (EAMI), arterial thrombosis (TAMI), venous thrombosis (VAMI) and non-occlusive mesenteric ischaemia (NOMI). Although they have different clinical and pathophysiological features this does not facilitate early diagnosis of the disease.

Twenty-five percent of the cardiac output goes to the splanchnic circulation at rest increasing to 35 % in the postprandial state. Seventy percent of mesenteric blood flows to the mucosa and submucosa [10] and microscopic changes of ischaemia can be detected within minutes [11]. Although the gut can survive a 75 % reduction in blood flow for up to 12 h without significant injury [12], irreversible bowel damage occurs within 6 h of complete vascular occlusion [13].

Untreated, AMI will cause mesenteric infarction, intestinal necrosis, an overwhelming inflammatory response and death. Early intervention can halt and reverse this process leading to a full recovery while failure to recognize AMI before intestinal necrosis has developed is responsible for the high mortality of the disease [14–16]. Early diagnosis and prompt treatment are the goals of modern therapy, but diagnosis is difficult particularly in the early stages when intervention would be of most benefit. A high index of suspicion in the elderly patient with pain out of proportion to clinical signs and an untreated cardiac arrhythmia is not an adequate baseline. In many studies up to 20 % of patients had no pain recorded [2, 6, 7, 17–24] and in one study 65 % of patients were intubated at the time of referral [25]. Moreover, many patients have peritonitis at presentation.

Although mortality rates have declined over the past 50 years [5, 26] they remain unacceptably high at 50–69 % [6, 27–29]. Overall 26 % of people admitted to hospital with acute mesenteric ischaemia will be alive a year later. However, those patients who are discharged alive have a reasonably good prognosis given the prevalence of significant co-morbidities among that cohort with 84 % alive at one year and 50–77 % at 5 years [18, 30–32]. Ten year survival of almost 30 % has been reported [18, 32]. A median survival of 52 months has been reported in patients with arterial occlusive AMI who survived their acute hospital admission [9].

There are no randomized controlled trials to guide treatment and the published literature contains a high ratio of reviews to original data. Much of that data comes from case reports and often small, retrospective series with no clearly defined treatment criteria.

The aim of these guidelines is to provide recommendations for practice that will lead to improved outcomes for patients.

Materials and methods

Definitions

For the purpose of these guidelines, acute mesenteric ischaemia (AMI) is defined as sudden acute arterial or venous occlusion or drop in circulating pressure resulting in insufficient blood flow within the mesenteric circulation.
to meet the metabolic demands placed upon it. Isolated colonic ischaemia and focal segmental ischaemia secondary to adhesions, hernias or other forms of extrinsic compression are excluded. Chronic mesenteric ischaemia and ischaemic colitis are separate entities and are not considered in these guidelines.

Search strategy and consensus approach

The European Society for Trauma and Emergency Surgery (ESTES) Study Group was formed in 2013 with the aim of developing guidelines for the management of AMI. Comprehensive computer database literature searches were performed using the indexed online database MEDLINE/PubMed using the Medical Subject Heading (MeSH) thesaurus keywords “mesenteric ischaemia”, “bowel ischaemia” and “bowel infarction”. Searches were limited to human studies. Abstracts from original publications were screened for relevance and full publications evaluated where appropriate. Lists of quoted literature within these articles were also screened for additional relevant publications.

After an initial systematic review of the literature by the whole group, the steering group formulated questions using a modified Delphi process [33]. The evidence was reviewed and recommendations formulated and agreed by the whole group. The classification system used to determine the strength of evidence (LOE) is given in Table 1 [34].

| Level of evidence | Definition |
|-------------------|------------|
| IA                | Evidence from meta-analysis of randomized controlled trials |
| IB                | Evidence from at least one randomized controlled trial |
| IIA               | Evidence from at least one controlled study without randomization |
| IIB               | Evidence from at least one other type of quasi-experimental study |
| III               | Evidence from non-experimental descriptive studies such as comparative studies, correlation studies and case controlled-studies |
| IV                | Evidence from expert committee reports or opinions or clinical experience of respected authorities or both |

Presentation and clinical diagnosis

Which clinical factors should arouse suspicion of AMI in the acute abdomen?

Answer: Most patients present with abdominal pain of sudden onset. The early phase of AMI can be characterized by an initial discrepancy between the severity of the abdominal pain and minimal findings on physical examination. Patients can also present with symptoms of nausea, vomiting and initial forced evacuation, early in the course of the disease. The location of pain varies, but as ischemia progresses to infarction, it becomes diffuse. The development of transmural infarction may also be signalled by fever, bloody diarrhoea and shock.

Background: The available evidence comes from level II and III studies, with mostly small and retrospective observational case-series. However, they all consider pain as the main symptom in most cases [14, 35]. The classical presentation has been described as pain out of proportion to the findings on clinical examination [10, 19, 36–41] but in 20 to 25% of patients the initial presentation resembles an acute abdomen from another cause [36, 42, 43]. Other frequent symptoms associated with pain in the early course include nausea (93%), vomiting (80%) and diarrhoea (48%) [19, 40, 41]. Klass’ classical description [44] of the onset of abdominal pain with sudden simultaneous passage of stools as a characteristic sign of AMI is also reported in recent studies [39, 43, 45]. However, these symptoms are not specific for AMI.

Features in the patient’s medical history can be important, particularly in the elderly presenting with 2–3 h of continuous abdominal pain [46]. A retrospective series of 215 AMI patients identified significant comorbidities that predispose to AMI such as ischaemic heart disease, atrial fibrillation, hypertension, diabetes mellitus or renal insufficiency in most patients [47]. Another retrospective series of 47 patients over 13 years observed atrial fibrillation in all 14 patients with arterial embolism and ischemic cardiomyopathy in 18 of 20 cases of arterial thrombosis [48]. As the disease progresses and ischemia leads to intestinal necrosis, pain becomes more diffuse and signs of peritoneal irritation [14] and bloating appear [39]. The patient may develop bloody diarrhoea, fever, signs of shock, multiple organ failure and a reduction in consciousness [37, 39].

Recommendation: Acute mesenteric ischaemia (AMI) should be suspected in patients with acute abdominal pain in whom there is no clear diagnosis, particularly when the pain is disproportionate to the physical examination findings and in the elderly with a history of cardiovascular comorbidities (LOE: III).
Are there any clinical features to distinguish the aetiology of AMI?

**Answer:** Clinical assessment does not reliably distinguish between mesenteric arterial embolism or arterial thrombosis. However, the four aetiological types of AMI have been associated with different characteristics and risk factors (Table 2). EAMI is characterized by a sudden onset of pain and is frequently associated with atrial fibrillation. TAMI has a more indolent course and is often associated with a history of abdominal angina and weight loss suggestive of undiagnosed chronic mesenteric ischaemia. VAMI appears in younger patients, sometimes with several days of mild symptoms. It is associated with hypercoagulable states, cirrhosis, severe pancreatitis, abdominal trauma and advanced malignancy. NOMI is often silent as it occurs in patients that are critically ill and often ventilated.

**Background:** Embolism is the most frequent cause of mesenteric ischaemia (45 %) [10]. Cardiac ischemia, tachyarrhythmia, rheumatic fever, and other conditions that predispose to the formation of atrial thrombi are risk factors of the disease [35, 36, 38, 42, 49].

Approximately 33 % of patients present with a history of recent embolism [36, 39] and the absence of suitable anticoagulant treatment in these patients should increase suspicion of EAMI [21, 35, 36, 42]. The sudden onset of severe pain with spontaneous emptying of the bowel (vomiting and diarrhoea) but no significant physical findings is a classic sign of an EAMI. If a potential source of emboli can be identified, this “clinical triad” is present in 40–80 % of patients [38].

Arterial thrombosis accounts for approximately 25 % of cases of AMI [10]. These patients usually report prodromal symptoms of mesenteric angina [36] (postprandial abdominal pain, nausea and weight loss) before the acute episode resulting from pre-existing vascular insufficiency [10, 39]. The main risk factors for TAMI are atherosclerotic disease and dyslipidaemia [49, 50]. There may be a history of other vascular events and previous vascular surgery.

Venous thrombosis represents 10 % of cases of patients with acute mesenteric ischaemia and usually occurs in a younger population. While thromboembolic AMI is more common in the over 60s, VAMI tends to occur in people over 40 [36, 47, 51, 52]. Although occasionally idiopathic, most patients have an identifiable risk factor [10, 51, 53]. Up to 50 % of patients with VAMI report a previous deep venous thrombosis or pulmonary embolism [54]. Other risk factors include hypercoagulability states (protein C and S deficiency, polycythaemia or Leiden factor V mutation), portal hypertension, abdominal trauma, abdominal infection, acute pancreatitis, malignancy, nephrotic syndrome, cirrhosis or splenomegaly [10, 40, 49, 51–53, 55–57]. Leiden factor V mutation is the most common associated hypercoagulability state and is reported in 20–40 % of VAMI cases [40]. Oral contraceptives, pregnancy and the puerperium are risk factors in young women [35, 58]. Venous vascular occlusion is usually peripheral, involving short segments of bowel [53]. The onset of VAMI is characterized by subacute abdominal pain that may develop over a period of up to 2 weeks. Half of the patients complain of nausea and vomiting. Untreated cases may result in portal hypertension with the development of oesophageal varices [39]. VAMI is not usually associated with postprandial syndrome, although bloating, abdominal distension, fever and occult blood in stools may be present [59].

NOMI is responsible for about 20 % of cases of mesenteric ischaemia. It usually occurs in patients that are critically ill, sedated and artificially ventilated and is difficult to recognize. It is poorly understood, but can be explained by a combination of low cardiac output and vasoconstriction. Risk factors for NOMI include age over 50, history of acute myocardial infarction, congestive heart failure, aortic insufficiency, cardiopulmonary bypass, kidney or liver disease.
or major abdominal surgery. Notably, many patients with NOMI may have none of these factors [10].

The diagnosis should be suspected in patients with mesenteric hypoperfusion secondary to circulatory shock or vasoactive drugs (including amines, cocaine and digitalis) when there is a significant unexpected deterioration in their clinical course [40, 41, 43, 60]. Acute or insidious pain (without defecation), bloating, abdominal distension and the presence of occult blood in the stools are all consistent with NOMI in a critically ill patient [10, 21, 36, 45, 54]. Most patients display signs of sepsis and abdominal distension as a late clinical sign [10].

Mitsuyoshi et al. [61] suggested diagnostic criteria for NOMI in the critically ill patient consisting of 3 of: ileus or abdominal pain, need for catecholamines, episode of hypotension or rising level of transaminases. Although they were able to demonstrate early detection and improved survival, the numbers involved were small.

Large doses of vasoressors alone can cause bowel ischaemia by non-occlusive, low perfusion mechanisms (NOMI). AMI has been associated with drug toxicity. Several case reports link cardiotoxins, such as digitalis, in combination with furosemide-induced fluid depletion, calcium-channel blockers [36], cocaine (linked to arterial thrombosis), organophosphates, ergotamine, phenobarbital, ethylene glycol or tricyclic antidepressants to NOMI in ICU patients. Snake bites have also been associated with NOMI [62, 63].

NOMI has also been described in patients who have undergone the stress of a surgical procedure or trauma and are receiving enteral nutrition in intensive care units. The reported incidence of AMI in these patients is 0.3–8.5 % [10, 64]. The proposed mechanism is an imbalance between demand (created by the enteral feeding) and supply (decreased by systemic hypo-perfusion and mesenteric vasoconstriction).

**Recommendations:** AMI secondary to an arterial embolism (EAMI) should be suspected in patients with atrial fibrillation who have a sudden onset of abdominal pain. AMI resulting from arterial thrombosis (TAMI) should be suspected in patients with evidence of atherosclerotic disease particularly with a recent history of postprandial syndrome. AMI due to venous thrombosis (VAMI) should be suspected in patients with hypercoagulable states. Non-occlusive mesenteric ischaemia (NOMI) should be suspected in critically ill patients with an unexpected deterioration in their clinical condition (LOE: III).

**Can interventional procedures precipitate AMI?**

**Answer:** Any procedure which involves vascular manipulation (even unintentional) can precipitate AMI.
**Background:** The moribund patient with significant co-morbidities and poor performance status is unlikely to benefit from intervention. A number of factors including admission from a nursing home, or partial dependence, pre-existing ‘do not attempt resuscitation’ order, and class 4 wound before surgery are all associated with increased mortality [68]. So too are coma, artificial ventilation, acute renal failure, chronic obstructive pulmonary disease, myocardial infarction within the preceding 6 months as well as preoperative sepsis, major surgery, emergency procedure, duration of surgery and postoperative complications [68].

Most of the literature considers old age and late diagnosis as bad prognostic factors for arterio-occlusive disease. However, in VAMI longer duration of symptoms before hospital admission may be related to better outcome. With arterio-occlusive AMI a cut off point of 60-65 years and 24 h from the onset of symptoms are associated with better prognosis [7, 14, 21, 30]. One study reported thirty day survival of 81% for patients with AMI under the age of 71. This fell to 30% between 71 and 84 and 7% in the over 84 s [28]. It was associated with increasing rates of non-resectable gangrene in these age groups of 9, 45 and 79%, respectively.

In a series of patients with AMI mortality was 10.6% if operated in the first 24 h after onset of symptoms vs. 72.9% if operated after 24 h [14].

In arterial occlusion, all symptoms but abdominal pain indicate disease progression. The presence of peritoneal irritation is associated with bowel necrosis and worse prognosis [14, 42]. Renal failure and acidosis resulting from shock and sepsis are independent risk factors for mortality [7, 35].

In a retrospective study of 58 patients resection (at first or second look procedure) and no recent major cardiovascular intervention were associated with better survival rates [21]. A larger retrospective series of 124 patients identified older age, bandemia, elevated serum aspartate aminotransferase, increased blood urea nitrogen and metabolic acidosis as independent predictors of death in AMI [7].

APACHE-II and P-POSSUM are not accurate scoring systems for outcomes after emergency surgery and P-POSSUM may under-predict mortality from AMI [69]. However, they may provide a useful indicator of morbidity and mortality. Other scoring systems for predicting outcome from AMI have shown early promise, but require validation in further studies [2, 30, 68].

**Recommendation:** Management decisions should not be based exclusively on clinical findings. However, patients with advanced age, late presentation, peritonitis and signs of organ failure are unlikely to benefit from invasive procedures and should be considered for palliative care only (LOE: III).

**Diagnosis**

**Are there sensitive and specific laboratory tests that can be used for early detection of AMI?**

**Answer:** There is no specific laboratory test that can be routinely used for early detection of AMI.

**Background:** The ideal plasma biomarker for AMI should be specific for bowel ischemia and highly sensitive. As ischemia starts from the mucosa and progresses to the serosa, a mucosa-derived marker would be most useful for early diagnosis [70]. The most promising plasma markers are intestinal fatty acid binding protein (I-FABP) and α-glutathione S-transferase (GST), originating from mucosa of the small bowel and D-lactate which is produced by gut bacterial organisms such as *Escherichia coli* [71, 72]. These markers may have a potential use as early diagnostic tools in AMI, but none of them has yet entered routine clinical practice.

Serum L-lactate is a specific marker of tissue hypo-perfusion [73]. The liver can clear large quantities of L-lactate from the porto-mesenteric circulation and as a result serum lactate level does not correlate with intestinal infarction [74]. Lactic acidosis develops late in the course of AMI with extensive transmural infarction and tissue hypoperfusion due to sepsis. At that point mortality is already in the order of 75% [75].

The fibrinolytic marker D-dimer does not differentiate patients with AMI from those with non-acute mesenteric ischemia and that there is no difference in D-dimer levels between patients with resectable and irresectable bowel necrosis [76].

The most common laboratory abnormalities found in AMI are hemoconcentration, leukocytosis, metabolic acidosis with high anion gap and lactate concentration, and high levels of serum amylase, aspartate aminotransferase, lactate dehydrogenase and creatine phosphokinase. None of these is sufficiently sensitive or specific to diagnose AMI [10, 77].

**Recommendations:** A normal serum lactate level does not exclude AMI and should not be used for diagnosis (LOE: III).

Routine laboratory tests reflect disease progression in AMI, but should not be used for diagnostic purposes (LOE: III).

**What is the most sensitive and specific test for the detection of AMI?**

**Answer:** The most sensitive and specific diagnostic tool is biphasic multidetector computed tomography (MDCT) with intravenous contrast.
Background: The diagnostic work-up of AMI requires a non-invasive test that confirms the diagnosis and differentiates it from other abdominal pathology. A plain abdominal radiograph has no role in the early detection of AMI, since a normal radiograph does not exclude the diagnosis. Radiographic signs in patients with AMI are nonspecific and appear when bowel infarction has already occurred [78].

Percutaneous angiography has been replaced as the gold standard for diagnosis of suspected AMI by MDCT. No relevant trials supporting the use of angiography for diagnosis can be found in the recent literature [79, 80]. MDCT should be the first line imaging method in suspected AMI due to its high diagnostic accuracy [81–85]. This imaging modality also allows other causes of acute abdominal pain to be excluded.

In this context biphasic CT involves the acquisition of scans in the arterial and venous phases. Scans are also acquired before intravenous contrast is given. Pre-contrast scans detect vascular calcification, hyper-attenuating intravascular thrombus and intramural haemorrhage, while contrast-enhanced CT allows the identification of thrombus in the mesenteric arteries and veins, abnormal enhancement of the bowel wall and the presence of embolism or infarction of other organs. Sagittal reconstructions are used to assess the origin of the mesenteric arteries [83]. The use of oral contrast is generally not feasible in patients with AMI. The transit time for oral contrast through the bowel will delay definitive treatment in AMI and the associated vomiting and adynamic ileus limit the useful passage of oral contrast material [83, 86].

MDCT has a high specificity and sensitivity [82]. A meta-analysis of six primary studies using MDCT on 619 cases with suspected AMI showed a pooled sensitivity of 93.3 % (95 % confidence interval 82.8, 97.6 %) and a pooled specificity of 95.9 % (95 % confidence interval 91.2, 98.2 %). Among confirmed cases of AMI, final clinical diagnoses were EAMI/TAMI in 69 % of patients, VAMI in 15 % and NOMI in 16 % [87].

The high diagnostic accuracy of MDCT is based on specific features of AMI such as occlusion of mesenteric vessels and the non-specific appearance of bowel wall thickening and intestinal pneumatosis [88]. Some of these features, like diameter of the small mesenteric vessels or gas bubbles in intestinal pneumatosis, are no larger than 1–2 mm which requires a high spatial resolution achieved with MDCT with a collimation of 1.25–2.5 mm in the arterial or the portal venous phase [83, 88]. Pneumatosis Intestinalis (presence of air within the bowel wall) usually indicates transmural infarction in AMI, particularly if it is associated with portomesenteric venous gas, but this sign is not specific for either infarction or ischemia.

NOMI represents the most difficult diagnostic challenge in AMI; usually these critically ill patients are sedated and intubated and diagnosis may rely only on clinical suspicion and imaging studies. The administration of intravenous contrast may be contraindicated, hence a lesser sensitivity and utility of MDCT [89]. The diagnosis of NOMI should be confirmed by selective catheter angiography [90, 91]. On CT, the bowel wall of the involved segments may be normal or thickened and the pattern of enhancement is variable ranging from absent or diminished to increased, while fat stranding of the mesentery and ascites are usually visible [83].

The CT findings in NOMI are poorly understood [86] although in two published papers, with a total of 6 cases, that specifically addressed the CT findings of surgically and pathologically proven NOMI [92, 93] the reported CT findings consisted of diffuse narrowing of the SMA, poor visualization of its secondary branches, bowel distension, thin and poorly enhancing bowel wall, and intestinal pneumatosis which are similar to the findings of acute occlusive AMI, except for the absence of thrombus/embolus. The most common features associated with AMI are described in Table 3.

Recommendations: In cases of suspected AMI, multidetector computerised tomography scanning (MDCT) with intravenous contrast should be performed immediately. The use of oral contrast will add significant delay to the MDCT and should be avoided (LOE: III).

Percutaneous angiography should not be used for initial diagnosis of AMI except where NOMI is suspected (LOE: III).

Is there a role for diagnostic laparoscopy in patients with AMI?

Answer: Laparoscopy can be used for diagnosis and second-look.

Background: Several articles with small series of patients address the use of laparoscopy in AMI [94–96]. In cases of uncertainty regarding the diagnosis or the extent of bowel necrosis, laparoscopy can offer a minimally invasive way to assess it, even in the ICU (bedside laparoscopy). Laparoscopic second-look procedures can be offered in a planned or on-demand fashion. However, there is no strong evidence to support the routine use of laparoscopy in AMI.

Recommendations: There is insufficient evidence to support the routine use of laparoscopy in AMI (LOE: IV).
Table 3 Radiological features associated with AMI

| Characteristic                          | EAMI–TAMI                                               | VAMI                                         | NOMI                                        |
|----------------------------------------|---------------------------------------------------------|----------------------------------------------|---------------------------------------------|
| Bowel wall                             | Thinning (“paper thin wall”), no change, or thickening with reperfusion | Thickening                                   | No change or thickening with reperfusion    |
| Attenuation of bowel wall on unenhanced CT | Not characteristic                                      | Low with oedema; high with haemorrhage       | Not characteristic                          |
| Enhancement of bowel wall on contrast-enhanced CT | Diminished, absent, target appearance or high with reperfusion | Diminished, absent, target appearance, or increased | Diminished, absent, heterogeneous in distribution |
| Bowel dilatation                       | Not apparent                                            | Moderate to prominent                        | Not apparent                                |
| Mesenteric vessels                     | Defect or defects in arteries, arterial occlusion, SMA >SMV in diameter | Defect or defects in veins, venous engorgement | No defect, arterial constriction             |
| Mesentery                              | Not hazy until mesenteric infarction occurs              | Hazy with ascites                           | Not hazy until mesenteric infarction occurs |

Modified from Furukawa et al. [83]

SMA superior mesenteric artery, SMV superior mesenteric vein

**Treatment**

**What are the goals of resuscitation and which fluid should be used?**

**Answer:** The main goal of resuscitation is the restoration of adequate tissue/organ perfusion. Supplementary oxygen should be given and crystalloids are the fluid of choice.

**Background:** The principal goals of managing the patient with AMI can be summarized with the 3 “Rs”: Resuscitation, Rapid diagnosis and early Revascularization before there is significant progression of the systemic inflammatory response. The main goal of fluid resuscitation is the restoration of adequate tissue/organ perfusion [97–99]. Supplementary oxygen should be given [100] and the evaluation of organ delivery of oxygen assessed using accepted clinical markers such as peripheral perfusion, mental status, and urine output [97, 100].

A recent Cochrane Review [101] has shown no advantage of colloids over crystalloids in reducing mortality when used for intravenous fluid resuscitation. The choice of fluid will have a cost implication, and colloids are more expensive than crystalloids. As there is no evidence that colloids improve survival rates or reduce morbidity, crystalloids should be preferred on economic grounds. Evidence suggests that the use of hydroxyethyl starch might increase mortality and should be avoided until further proof of safety can be provided [101–105].

**Recommendations:** Supplementary oxygen should be given immediately (LOE: III).

Fluid volume status should be quickly assessed and fluid replacement should start promptly but should not delay diagnosis and intervention (LOE: IV).

Crystalloids should be used for fluid replacement, hydroxyethyl starch should be avoided (LOE: Ia).

**Is there a role for vasopressor drugs?**

**Answer:** Vasopressors reduce splanchnic perfusion and should be avoided in AMI whenever possible. Pressors also reduce the effectiveness of angiography. However, when required consideration should be given to using a pressor which has less effect on mesenteric blood flow.

**Background:** AMI results from insufficient blood flow within the mesenteric circulation to meet the metabolic demands placed upon it. This may be confounded by hypovolaemia and circulatory failure. The use of vasopressors to improve cardiac function should be balanced against the adverse effect of further splanchnic vasoconstriction [3, 106]. Consideration should be given to the use of drugs such as dobutamine, low dose dopamine and milrinone, which have been shown to have less impact on mesenteric blood flow [39]. Vasopressors should not be used until the patient has been adequately volume resuscitated. Cardiac output can also be improved by rate control in atrial fibrillation. However, digoxin and other cardiac glycosides also reduce flow in the splanchnic circulation and should be avoided for the control of atrial fibrillation/flutter in patients with AMI [40, 96, 98].

**Recommendations:** Vasopressor drugs should be avoided in AMI. If vasopressor drugs are required after adequate volume replacement, preference should be given to those with minimal effect on the splanchnic circulation (LOE: IV).

Cardiac glycosides should not be used as first line treatment of atrial fibrillation/flutter in AMI (LOE: IV).
Is there a role for antibiotics?

**Answer:** AMI affects the mucosa first and bacterial translocation is an early event in the progression of AMI. Broad-spectrum antibiotic cover should be given.

**Background:** Loss of the integrity of the mucosal barrier facilitates bacterial translocation and occurs in the early stages of AMI. Although no specific studies have examined the role of prophylactic antibiotics in AMI, broad spectrum antibiotics (such as a penicillin or a third generation cephalosporin in combination with metronidazole) would be expected to reduce the consequences of bacterial translocation and should be given early [107].

**Recommendation:** Broad spectrum antibiotics should be administered early in the course of AMI (LOE: IV).

What is the specific treatment for AMI?

**Arterial embolism (EAMI)**

**Answer:** Open embolectomy is widely used in this scenario. However, if expertise and appropriate resources are available, and there is no evidence of bowel necrosis, endovascular techniques should be attempted.

**Background:** The established treatment is open surgical embolectomy. However, an increasing number of cases of successful percutaneous treatment have been reported with overall results comparable to the open approach [91, 106].

Open embolectomy is usually performed via a midline incision approaching the SMA just below the pancreas at the mesenteric root [98]. A transverse arteriotomy is then made after proximal and distal clamping and embolectomy catheters are used to clear the artery proximally and distally. High pressure proximal flushing should be avoided so as not to dislodge the thrombus in the aorta and produce further emboli. After completing the thrombectomy the artery should be flushed gently with heparinized saline. The arteriotomy is then closed in a standard fashion.

Endovascular embolectomy is achieved by percutaneous mechanical aspiration [108] or thrombolysis [109, 110] and permits percutaneous transluminal angioplasty (PTA), if necessary, with or without stenting [111, 112].

**Recommendation:** In cases where immediate surgical intervention is not required the decision to perform endovascular or open vascular surgery for EAMI should be determined by the personal experience and technical capabilities of the surgeon and the available resources (LOE: IV).

When EAMI is identified during a laparotomy an open embolectomy should be performed (LOE: IV).

**Arterial thrombosis (TAMI)**

**Answer:** Endovascular treatment should be the first choice for TAMI whenever possible.

**Background:** Endovascular treatment should be considered as soon as possible for acute thrombosis of a diseased superior mesenteric artery (SMA) [91, 98, 106, 113, 114]. This should be performed before intestinal infarction occurs and when the ischaemia is potentially reversible. The commonest interventions are PTA and stenting. Other endovascular techniques include percutaneous aspiration thrombectomy, local fibrinolysis or intra-arterial drug perfusion (such as heparin or papaverine).

If surgery is needed to resect ischaemic bowel before vascular intervention, or when percutaneous treatment has failed, retrograde open mesenteric stenting (ROMS) has been suggested [113].

Conventional bypass surgery is another option [98]. There are a variety of bypass procedures, providing either antegrade or retrograde flow, with vein or synthetic grafts. An antegrade bypass from supraceliac aorta to superior mesenteric trunk using an endogenous vein graft will give the best result. An alternative approach would be a renal-mesenteric bypass. However, the most practical option for proximal mesenteric atherosclerotic occlusive disease is a retrograde bypass from common iliac with a synthetic graft.

Where vascular expertise is not available it may be reasonable to resect the necrotic bowel first and transfer the patient for urgent interventional angiography or vascular surgery [91].

**Recommendations:** When bowel integrity has not been compromised, endovascular techniques should be performed as first line treatment for TAMI (LOE: III).

When a laparotomy has been performed for TAMI the choice of vascular intervention will depend on available resources and expertise (LOE: IV).

When vascular expertise is not available it may be reasonable to resect the necrotic bowel first and transfer the patient for urgent interventional angiography or vascular surgery (LOE: III).

**Venous ischaemia (VAMI)**

**Answer:** The first line treatment for mesenteric venous thrombosis is anticoagulation.

**Background:** VAMI is usually managed without surgery. Anticoagulation with a continuous infusion of unfractionated or low molecular weight heparin is the first line treatment for VAMI and should also be started in patients diagnosed at operation [80, 91, 98, 106, 115–117]. Isolated thrombosis of the superior mesenteric vein is usually
compensated by sufficient collateral circulation. However, additional complete thrombosis of the portal vein leads to venous infarction of segments of small intestine of varying severity and may require laparotomy.

Patients who deteriorate during medical treatment can be considered for endovascular treatment. Many techniques have been described such as transjugular intrahepatic portosystemic shunting (TIPS) with mechanical aspiration thrombectomy and direct thrombolysis, percutaneous transhepatic thrombolysis, indirect thrombolysis via the SMA and thrombolysis via a surgically placed superior mesenteric vein (SMV) catheter.

A number of case-series advocate prompt direct thrombolysis on the basis of reported reduction in both early complications (infarction) and late sequelae (portal hypertension) [116]. Contraindications to thrombolytic treatment are well established and can be divided into absolute (central nervous system tumours, recent haemorrhagic stroke, gastrointestinal (GI) bleed and uncontrolled hypertension) and relative (pregnancy, remote history of GI bleeding, and recent major surgery).

**Recommendations:** Systemic anticoagulation should be started as soon as possible in VAMI (LOE: III).

Endovascular intervention should be offered to patients with VAMI who deteriorate during medical therapy (LOE: IV).

**Non-occlusive mesenteric ischaemia (NOMI)**

**Answer:** The first line treatment for NOMI is medical therapy with direct infusion of vasodilators into the SMA.

**Background:** The treatment of NOMI is based on correcting the clinical or pharmacological conditions that generate splanchnic vasoconstriction, improving mesenteric perfusion and early recognition and resection of infarcted bowel [99].

The main factor in improving mesenteric perfusion is the restoration of circulatory volume and hemodynamic stability coupled with the use of vasodilators administered directly into the SMA in order to reverse the intestinal vasospasm that causes ischemia.

The diagnosis of NOMI should be confirmed by selective mesenteric angiography and, if there are no contraindications, the infusion of vasodilators directly into the SMA [90]. The best vasodilator drug appears to be prostaglandin E1 (alprostadil) given as a 20 mcg bolus followed by 60–80 mcg/24 h infusion [90]; papaverine (30–60 mg/h) has been shown to reduce the mortality rate for NOMI from 70 to 50–55 % and is an acceptable alternative [1, 10]. Other prostacyclin analogues have also been used [61].

The decision to intervene surgically is based on the presence of peritonitis, perforation, or overall worsening of the patient’s condition [99].

**Recommendation:** NOMI should be managed by correcting the underlying cause wherever possible and improving mesenteric perfusion by direct infusion of vasodilators. Infarcted bowel should be excised (LOE: III).

**How should a patient with peritonitis secondary to AMI be managed?**

**Answer:** The common feature in the management of AMI is the need for surgical exploration in the presence of peritonitis. Patients with AMI and signs of peritonitis should undergo immediate surgery if comorbidities and clinical condition make curative treatment possible. Surgical intervention should also be considered if the patient’s condition deteriorates. With severe pre-existing medical conditions, pre-terminal state or extreme old age, the decision to proceed to laparotomy may not be appropriate.

**Background:** Across the literature there is agreement that peritonitis secondary to bowel necrosis mandates surgery without delay if curative treatment is to be achieved [98, 106]. All other priorities (type of AMI, level of occlusion, etc.) are secondary and should be managed accordingly.

**Recommendation:** Patients with AMI and signs of peritonitis should undergo immediate surgery if comorbidities and clinical condition make curative treatment possible (LOE: III).

Patients considered unsalvageable should have palliative care (LOE: IV).

**What is the role of Damage Control Surgery in AMI?**

**Answer:** Damage Control (DCS) is the surgical modality of choice in the critically ill patient with AMI.

**Background:** Patients with AMI who have severe sepsis or septic shock and undergo life-saving surgery should have a damage control approach. [118–121]. This includes immediate laparotomy with resection of ischaemic bowel (and no anastomosis or stoma), open thrombectomy (if indicated), transfer to the intensive care unit to continue resuscitation prior to planned definitive procedures [122]. A temporary abdominal closure via a negative pressure wound therapy (NPWT) device should be considered since they have been shown to promote wound healing and facilitate subsequent abdominal closure [123, 124]. A scheduled ‘second look’ procedure should be performed within 48 h [125, 126].

**Recommendation:** Patients with AMI who have severe sepsis or septic shock should undergo life-saving damage control surgery (DCS) (LOE: III).

**How should bowel viability be assessed at operation?**

**Answer:** Assessment is based on the macroscopic appearance of the bowel: its colour, motility and bleeding of cut ends.
Background: Necrotic bowel will be clearly identifiable at laparotomy [122, 127]. The viability of the remaining bowel should be determined after the patient has been adequately resuscitated and any resection/revascularization performed [122]. In the acute setting, hypotension, vascular impairment and the concurrent use of vasopressors may confound this assessment and could result in excessive resection [106]. It is often better to adopt a damage limitation approach and schedule a second-look procedure under these circumstances.

Intra-operative assessment with Doppler ultrasound of the vascular arcade, [128, 129], fluorescein angiography [127, 130] and indocyanine green angiography [131] have shown promise, but not been used extensively.

Recommendations: Necrotic bowel should be removed if the patient is considered salvageable (LOE: III).

Ischemic bowel should be reassessed after adequate fluid resuscitation and revascularization. If any doubt remains about the viability of the bowel, a second-look procedure should be performed (LOE: IV).

What limits should be observed in extensive bowel resection?

Answer: The removal of large amounts of small bowel can result in short bowel syndrome (SBS) and intestinal failure. SBS is associated with poor quality of life and a morbidity/mortality which increases with age and comorbidities. Thus extensive resections should be carefully considered.

Background: Vascular occlusion in TAMI usually occurs in the proximal SMA and the consequent ischemia may extend from the terminal portion of the duodenum to the transverse colon [36]. In contrast, in EAMI most emboli lodge in the superior mesenteric artery distal to the origin of the middle colic artery. This maintains perfusion of the inferior pancreaticoduodenal arteries and spares the proximal jejunum from ischaemia [10, 36, 132]. However, up to 15% of emboli in EAMI lodge at the origin of the SMA causing more extensive ischaemia.

Short bowel syndrome requiring total parenteral nutrition (TPN) has been reported in 13–31% of long-term survivors of AMI [9, 21, 31] and weight loss has been documented in 38% [31]. SBS generally occurs when less than 200 cm of functioning bowel remains [106].

Restoring bowel continuity will improve the functional results of extensive small bowel resection and may avoid long term TPN. It has been suggested that while permanent intestinal failure is likely with a residual 100 cm of small bowel and an end jejunostomy, the need for permanent TPN may be avoided with a minimum 65 cm of jejunum and a jejunoileal anastomosis, and 35 cm where the ileocecal region is preserved and a jejunoileal anastomosis performed [133].

When a residual small bowel length of 200 cm cannot be obtained, careful consideration should be given to the significant risk of resection, particularly in the elderly patients and in those with significant co-morbidities. In younger patients the option of long term parenteral nutrition or the option of subsequent intestinal transplantation could make a more extensive resection reasonable.

Recommendation: The benefits of extensive small bowel resection should be balanced against the resultant quality of life, morbidity and mortality especially in elderly patients. Restoration of bowel continuity following extensive resection will improve functional results and may avoid the need for long term TPN (LOE: III).

When is the most appropriate time to perform an anastomosis in a patient with AMI who needs bowel resection?

Answer: An anastomosis should be performed only in adequately resuscitated and stable patients when there is no question about the viability of the bowel.

Background: Bowel anastomosis should be avoided in the presence of severe sepsis or septic shock or when the patient is inadequately resuscitated. Where limited necrosis is found, there is no doubt about the viability of the remaining bowel, the patient has been adequately resuscitated and there is no evidence of shock, some authors advocate anastomosis with a planned second-look [94]. Laparoscopy can be useful in this circumstance [126]. There are no published studies that compare anastomotic techniques in AMI.

Stomas avoid the risks of anastomotic failure and permit easy examination of the bowel by inspection and/or endoscopy [106]. A mucous fistula of the distal bowel may be used for re-feeding in patients with very proximal jejunoileostomies [134]. Continuity can be restored later if appropriate.

Recommendation: Anastomosis should be avoided in patients with shock or multiple organ dysfunction (LOE: III).

If during a second look procedure there is still doubt about the viability of the bowel it should be exteriorised (LOE: IV).

What is the role of second-look laparotomy?

Answer: The second-look laparotomy plays an important role in AMI patients treated with curative intent and is the natural consequence of DCS.

Background: The use of second look procedures is associated with a significant reduction in morbidity (p = 0.002) [9] and mortality in selected patients leading to resection of ischaemic bowel in 38–71% of cases [14, 17, 18, 24, 29, 126, 135]. It is currently the best method to...
assess bowel viability after revascularization and resuscita-
tion and may be the best time to perform an anastomosis
and to close the abdomen after DCS.

**Recommendations:** After DCS a planned second-look
procedure should be performed within 48 h (LOE: III).
A scheduled second-look should also be considered
when there is concern about the possible progression of
bowel ischemia and there should be a low threshold for an
“on demand” second look procedure in AMI particularly
when a bowel anastomosis has been performed (LOE: III).

**Can we improve outcomes in terms of mortality
and morbidity?**

**Answer:** Outcomes for AMI can be improved by rapid
diagnosis, optimisation and intervention by revasculariza-
tion with or without resection.

**Background:** Mortality increases dramatically when
symptoms have been present for more than 24 h in AMI.
Numerous studies have shown that mortality is lowest if intervention is performed within 12 h of the onset of
symptoms. [18, 22, 25, 58, 136–139]. This is supported
by experimental work which has shown gut viability to be
100 % within the first 12 h of ischaemia. This drops to
54 % between 12 and 24 h and 18 % beyond 24 h [140].
The development of symptoms in VAMI is usually
slower than the other forms of AMI. A small retrospective
study of VAMI over 23 years suggested that patients pre-
senting within 3 days of the onset of symptoms had poorer
outcomes than those presenting with symptoms of longer
duration. The first group were more likely to undergo lap-
arotomy within 12 h of hospital admission (83 vs. 20 %)
[52]. This reflected rapid disease progression in the group
that presented sooner. In studies comparing the four aetio-
logical types of AMI, VAMI has the lowest mortality (11–
30 %) [5, 22, 30].

**Recommendation:** To improve outcomes in AMI a
prompt diagnosis should be achieved and revasculariza-
tion performed within 12 h from the onset of symptoms.
Resection of non-viable bowel should be performed with-
out delay (LOE: III).

**Is there a role for prevention?**

**Answer:** The diagnosis of AMI is difficult and often
delayed or overlooked. Primary prevention should be tar-
geted at managing the risk factors that predispose it. There
is little direct evidence for the benefit of secondary prophyl-
axis of AMI.

**Background:** Since TAMI is usually a marker for
advanced systemic atherosclerosis, it would seem rea-
sonable, where appropriate, to advise these patients to
stop smoking, modify their diet, lose weight and exercise
adequately. Diabetes and hypertension should be treated and
the use of statins and antiplatelet therapy considered [141].
Up to 60 % of patients with TAMI have previous symp-
toms of chronic mesenteric ischaemia (CMI) [9]. The mor-
tality of elective surgical intervention for CMI in selected
patients has been shown to be significantly lower than the
same procedures performed for TAMI [32]. However, there
is little evidence that elective intervention for CMI prevents
TAMI.

One-third of patients with EAMI have inadequately
treated atrial fibrillation at presentation [9] and a similar
number will have further emboli [3]. These patients should
be considered for anticoagulation [31].

Cho et al. advocate ‘vigilant surveillance and preserva-
tion of SMA patency’ after vascular reconstruction [32].
Although numbers were small, 60 % (3 of 5) of patients
who were treated for graft stenosis with stent/angioplasty
or further reconstruction had a successful outcome. How-
ever, all of these occlusions were symptomatic.

**Summary of recommendations**

1. Acute mesenteric ischaemia (AMI) should be
suspected in patients with acute abdominal pain
in whom there is no clear diagnosis, particularly
when the pain is disproportionate to the physical
examination findings and in the elderly with a his-
1. ESTES guidelines: acute mesenteric ischaemia (Level of evidence: III).
2. AMI secondary to an arterial embolism (EAMI) should be suspected in patients with atrial fibrillation who have a sudden onset of abdominal pain. AMI resulting from arterial thrombosis (TAMI) should be suspected in patients with evidence of atherosclerotic disease particularly with a recent history of postprandial syndrome. AMI due to venous thrombosis (VAMI) should be suspected in patients with hypercoagulable states. Non-occlusive mesenteric ischaemia (NOMI) should be suspected in critically ill patients with an unexpected deterioration in their clinical condition (Level of evidence: III).
3. Unexplained abdominal pain after any invasive procedure, particularly involving vascular manipulation, should lead to suspicion and investigation of AMI (Level of evidence: III).
4. Management decisions should not be based exclusively on clinical findings. However, patients with advanced age, late presentation, peritonitis and signs of organ failure are unlikely to benefit from invasive procedures and should be considered for palliative care only (Level of evidence: III).
5. A normal serum lactate level does not exclude AMI and should not be used for diagnosis (Level of evidence: III).
6. Routine laboratory tests reflect disease progression in AMI, but should not be used for diagnostic purposes (Level of evidence: III).
7. In cases of suspected AMI, multidetector computerised tomography scanning (MDCT) with intravenous contrast should be performed immediately. The use of oral contrast will add significant delay to the MDCT and should be avoided (Level of evidence: III).
8. Percutaneous angiography should not be used for initial diagnosis of AMI except where NOMI is suspected (Level of evidence: III).
9. There is insufficient evidence to support the routine use of laparoscopy in AMI (Level of evidence: IV).
10. Supplementary oxygen should be given immediately to all patients with AMI (Level of evidence: III).
11. Fluid volume status should be quickly assessed and fluid replacement should start promptly but should not delay diagnosis and intervention (Level of evidence: IV).
12. Crystalloids should be used for fluid replacement, hydroxyethyl starch should be avoided (Level of evidence: Ia).
13. Vasopressor drugs should be avoided in AMI. If vasopressor drugs are required after adequate volume replacement, preference should be given to those with minimal effect on the splanchnic circulation (Level of evidence: IV).
14. Cardiac glycosides should not be used as first line treatment of atrial fibrillation/flutter in AMI (Level of evidence: IV).
15. Broad spectrum antibiotics should be administered early in the course of AMI (Level of evidence: IV).
16. In cases where immediate surgical intervention is not required the decision to perform endovascular or open vascular surgery for EAMI should be determined by the personal experience and technical capabilities of the surgeon and the available resources (Level of evidence: IV).
17. When EAMI is identified during a laparotomy an open embolectomy should be performed (Level of evidence: IV).
18. When bowel integrity has not been compromised, endovascular techniques should be performed as first line treatment for TAMI (Level of evidence: III).
19. When a laparotomy has been performed for TAMI the choice of vascular intervention will depend on available resources and expertise (Level of evidence: IV).
20. When vascular expertise is not available it may be reasonable to resect the necrotic bowel first and transfer the patient for urgent interventional angiography or vascular surgery (Level of evidence: III).
21. Systemic anticoagulation should be started as soon as possible in VAMI (Level of evidence: III).
22. Endovascular intervention should be offered to patients with VAMI who deteriorate during medical therapy (Level of evidence: IV).
23. NOMI should be managed by correcting the underlying cause wherever possible and improving mesenteric perfusion by direct infusion of vasodilators. Infarcted bowel should be excised (Level of evidence: III).
24. Patients with AMI and signs of peritonitis should undergo immediate surgery if comorbidities and clinical condition make curative treatment possible (Level of evidence: III).
25. Patients considered unsalvageable should have palliative care (Level of evidence: IV).
26. Patients with AMI who have severe sepsis or septic shock should undergo life-saving damage control surgery (DCS) (Level of evidence: III).

27. Necrotic bowel should be removed if the patient is considered salvageable (Level of evidence: III).

28. Ischemic bowel should be reassessed after adequate fluid resuscitation and revascularization. If any doubt remains about the viability of the bowel, a second-look procedure should be performed (Level of evidence: IV).

29. The benefits of extensive small bowel resection should be balanced against the resultant quality of life, morbidity and mortality especially in elderly patients. Restoration of bowel continuity following extensive resection will improve functional results and may avoid the need for long term TPN (Level of evidence: III).

30. Anastomosis should be avoided in patients with shock or multiple organ dysfunction (Level of evidence: III).

31. If during a second look procedure there is still doubt about the viability of the bowel it should be exteriorised (Level of evidence: IV).

32. After DCS a planned second-look procedure should be performed within 48 h (Level of evidence: III).

33. A scheduled second-look should also be considered when there is concern about the possible progression of bowel ischemia and there should be a low threshold for an "on demand" second look procedure in AMI particularly when a bowel anastomosis has been performed (Level of evidence: III).

34. To improve outcomes in AMI a prompt diagnosis should be achieved and revascularization performed within 12 h from the onset of symptoms. Resection of non-viable bowel should be performed without delay (Level of evidence: III).

35. All patients with AMI should be advised to make appropriate lifestyle changes to reduce the consequences of vascular disease. Diabetes and hypertension should be treated (Level of evidence: IV).

36. Patients with proven CMI should be considered for elective revascularization (Level of evidence: IV).

37. Unless contraindicated, patients with emboli should be treated with life-long anticoagulation to reduce the risk of recurrence (Level of evidence: IV).

38. Patients with mesenteric artery thrombosis are at high risk of coronary thrombosis and they should be offered anticoagulants or antiplatelet therapy and a statin to reduce this risk (Level of evidence: IV).

39. Patients with mesenteric venous thrombosis should be investigated for thrombophilia and treated accordingly. Where indicated, they should have a minimum of 6 months of anticoagulation (Level of evidence: III).

40. Patients who have vascular stents or bypass procedures should have graft surveillance or stent follow up with duplex scanning or CT angiography to enable early detection and management of stenosis and occlusion (Level of evidence: IV).

Acknowledgments The project was funded by the European Society for Trauma and Emergency Surgery.

Compliances with ethical standards

Conflict of interest Jonathan Tilsed, Andrea Casamassima, Hayato Kurihara, Diego Mariani, Isidro Martinez, Jorge Pereira, Luca Ponzicetti, Andreas Shamiyeh, Fawzi al-Ayoubi, Luis Alberto Bagnaschino Barco, Martina Ceolin, Antonio Joao Gandra D’Almeida, Sandra Hilario, Aitor Landaluce Olavarria, M Mahir Ozmen, Luis Filipe Pinheiro, Martijn Poeze, George Triantos, Fernando Turegano Fuentes, Soledad Ugarte Sierra, Kjetil Soreide and Hakan Yanar declare that they have no conflict of interest (actual or potential) in this work.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Stoney RJ, Cunningham CG. Acute mesenteric ischemia. Surgery. 1993;114(3):489–90.

2. Haga Y, Odo M, Homma M, Komiya K, Takeda K, Koike S, Takahashi T, Hiraka K, Yamashita H, Tanakaya K. New prediction rule for mortality in acute mesenteric ischemia. Digestion. 2009;80(2):104–411.

3. Sise MJ. Mesenteric ischemia: the whole spectrum. Scand J Surg. 2010;99:106–10.

4. Huerta C, Rivero E, Montoro MA, Garcia Rodriguez LA. Risk factors for intestinal ischaemia among patients registered in a UK primary care database: a nested case control study. Aliment Pharmacol Ther. 2011;33:969–78.

5. Acosta S. Epidemiology of mesenteric vascular disease: clinical implications. Sem Vasc Surg. 2010;23:4–8.

6. Aouini F, Bouhaffa A, Baaazouli J, Khelifi S, Ben Maamer A, Houas N, Cherif A. Acute mesenteric ischemia: study of predictive factors of mortality. Tunis Med. 2012;90(7):533–536 (French).

7. Huang HH, Chang YC, Yen DH, Kao WF, Chen JD, Wang LM, Huang CI, Lee CH. Clinical factors and outcomes in patients with acute mesenteric ischemia in the emergency department. J Chin Med Assoc. 2005;68(7):299–306.
8. Endean E, Barnes SL, Kwolek C, et al. Surgical management of thrombotic acute intestinal ischemia. Ann Surg. 2001;233:801–8.
9. Edwards MS, Cherr GS, Craven TE, et al. Acute occlusive mesenteric ischemia: surgical management and outcomes. Ann Vasc Surg. 2003;17:72–9.
10. Oldenburg WA, Lau LL, Rodenberg TJ, Edmonds HJ, Burger CD. Acute mesenteric ischemia: a clinical review. Arch Intern Med. 2004;164(10):1054–62.
11. Robinson JWL, Mirkovich V, Winiusber F. Response of the intestinal mucosa to ischemia. Gut. 1981;22:512–27.
12. Boley SJ, Brandt LJ, Veith FJ. Ischemic disorders of the intestine. Curr Probl Surg. 1978;15(4):1–85.
13. Chin CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. A morphological, hemodynamic and metabolic reappraisal. Arch Surg. 1970;101:478–83.
14. Aliosmanoglu I, Gul M, Kapan M, Arikanoglu Z, Taskesen F,Basol O, Aldemir M. Risk factors effecting mortality in acute mesenteric ischemia and mortality rates: a single center experience. Int Surg. 2013;98(1):76–81.
15. Mansour MA. Management of acute mesenteric ischemia. Arch Surg. 1999;134(3):328–30.
16. Kassahun WT, Schulz T, Richter O, Hauss J. Unchanged high mortality rates from acute occlusive intestinal ischemia: six year review. Langenbecks Arch Surg. 2008;393:163–71.
17. Ryer EJ, Kalra M, Oderich GS, Duncan AA, Gloviczki P, Cha S, Bower TC. Revascularization for acute mesenteric ischemia. J Vasc Surg. 2012;55(6):1682–9.
18. Kougias P, Lau D, El Sayed HF, Zhou W, Huyhn TT, Lin PH. Determinants of mortality and treatment outcome following surgical interventions for acute mesenteric ischemia. J Vasc Surg. 2007;46(3):467–74.
19. Sreedharan S, Tan YM, Tan SG, Soo KC, Wong WK. Clinical spectrum and surgical management of acute mesenteric ischemia in Singapore. Singapore Med J. 2007;48(4):319–23.
20. Acosta-Merida MA, Marchena-Gomez J, Hemmersbach-Miller M, Roque-Castellano C, Hernandez-Romero JM. Identification of risk factors for perioperative mortality in acute mesenteric ischemia. World J Surg. 2006;30(8):1579–85.
21. Park WM, Gloviczki P, Cherry KJ Jr, Hallett JW Jr, Bower TC, Panneton JM, Schleck C, Listrup D, Harmsen WS, Noel AA. Contemporary management of acute mesenteric ischemia: Factors associated with survival. J Vasc Surg. 2002;35(3):445–52.
22. Inderbitzi R, Wagner HE, Seiler C, Stiernemann P, Gertsch P. Acute mesenteric ischemia. Eur J Surg. 1992;158(2):123–6.
23. Mishima Y. Acute mesenteric ischemia. Jpn J Surg. 1988;18(6):615–9.
24. Dahlke MH, Asshoff L, Popp FC, et al. Mesenteric ischaemia-outcome after surgical therapy in 83 patients. Dig Surg. 2008;25:213–9.
25. Eltarawy IG, Etman YM, Zenati M, Simmons RL, Rosengart MR. Acute mesenteric ischemia: the importance of early surgical consultation. Am Surg. 2009;75(3):212–9.
26. Schoots IG, Koffeman GI, Legemate DA, Levi M, van Gulik TM. Systematic review of survival after acute mesenteric ischemia according to disease aetiology. Br J Surg. 2004;91(1):17–27.
27. Haghighi PH, Lankarani KB, Taghavi SA, Marvasti VE. Acute mesenteric ischemia: causes and mortality rates over sixteen years in southern Iran. Indian J Gastroenterol. 2008;27(6):236–8.
28. Wadman M, Syk I, Elmstahl S. Survival after operations for ischaemic bowel disease. Eur J Surg. 2000;166:872–7.
29. Tsai M-S, Lin C-L, Chen H-P, Lee P-H, Sung F-C, Kao C-H. Long-term risk of mesenteric ischemia in patients with inflammatory bowel disease: A 13-year nationwide cohort study in an Asian population. Am J Surg. 2015;210(1):80–6.
30. Marchena-Gomez J, Acosta-Merida MA, Hemmersbach-Miller M, Conde-Martel A, Roque-Castellano C, Hernandez-Romero J. The age-adjusted Charlson Comorbidity Index as an outcome predictor of patients with acute mesenteric ischemia. Ann Vasc Surg. 2009;23(4):458–64.
31. Klempnauer J, Grothues F, Beks H, Pichlmayr R. Long-term results after surgery for acute mesenteric ischemia. Surgery. 1997;121(3):239–43.
32. Cho JS, Carr JA, Jacobsen G, et al. Long-term outcome after mesenteric artery reconstruction: a 37-year experience. J Vasc Surg. 2002;35:453–60.
33. Pinto A, Kosecoff J, Chassin M, Brook RH, Seiler C, Stirnemann P. Consensus methods: characteristics and guidelines for use. Am J Public Health. 1984;74(9):979–83.
34. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Developing clinical guidelines. West J Med. 1999;170(6):348–51.
35. Ozturk G, Aydinli B, Atamanalp SS, Yildirgan M, Ozogul B, Kısaoğlu A. Acute mesenteric ischemia in young adults. Wien Med Wochenschr. 2012;162(15–16):349–53.
36. Berland T, Oldenburg WA. Acute mesenteric ischemia. Curr Gastroenterol Rep. 2008;10(3):341–6.
37. Manley J, Bilski TR. Mesenteric ischemia. In: Brooks A, Mahoney PF, Cotton BA, Tai N, editors. Emergency surgery. Oxford: Blackwell Publishing; 2010. p. 50–51.
38. Block T. Acute occlusion of the superior mesenteric artery. Diagnosis and treatment. Acta Universitatis Upsaliensis 2010. Digital comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 599. ISBN: 978-91-554-7896-4.
39. Tenderla DA, LaMont JT. Acute mesenteric ischemia. Uptodate. 2013. http://www.uptodate.com/contents/acute-mesenteric-ischemia. Accessed 13 Aug 2013.
40. Dewitte A, Blais M, Coquin J, Fleureau C, Cassinotto C, Ouattara A, Janvier G. Diagnosis and management of acute mesenteric ischemia. Ann Franc Anest Reanim. 2011;30:410–420 (French).
41. Aboud B, Daher R, Boujaoude J. Acute mesenteric ischemia after cardio-pulmonary bypass surgery. World J Gastroenterol. 2008;14(35):5361–70.
42. Albandea Moreno C, Aguilar Urbano VM, Gonzalo Marin J, Rosales Zabal JM, Rivera Ingöin R, Fernández Gutiérrez Del Alamo F, Pérez Aisa A, Sánchez Cantos A. Acute mesenteric ischemia:importance of an early diagnosis. Rev Esp Enferm Digestion. 2009;110(9):661–662 (Spanish).
43. Martin MC, Wyers MC. Mesenteric vascular disease. In:Cronenwett JL, Johnston W, editors. Rutherford’s vascular surgery. 8th ed. Philadelphia: Elsevier Saunders; 2014. p. 2398–413.
44. Klass AA. Embolectomy in acute mesenteric occlusion. Ann Surg. 1951;134(5):913–7.
45. Boley SJ. Early diagnosis of acute mesenteric ischemia. Hosp Pract (Off Ed). 1981;16(8):63–71.
46. Brandt LJ, Boley SJ. AGA technical review on intestinal ischemia. Gastroenterology. 2000;118:954–68.
47. Vokurka J, Olejnik J, Jedlicka V, Vesely M, Ciernik J, Paseka T. Acute mesenteric ischemia. Hepatogastroenterology. 2008;55(85):1349–52.
48. Voltolina F, Pricolo R, Naldini G, Parziale A. Acute mesenteric ischemia. Analysis of 47 cases. Minerva Chir. 1996;51(5):285–292 (Italian).
49. Gupta N, Schwenk A, Borgstein R. Acute mesenteric ischemia on unenhanced computer-tomography. J Radiol Case Rep. 2010;4(9):24–30.
50. Caleb MG. Acute bowel ischemia after coronary bypass surgery - a catastrophic event. Singapore Med J. 2001;42(1):33–7.
51. Abu-Laban RB, Ho K, Walls RM. Acute mesenteric ischemia in a middle-aged patient: case report and discussion. J Emerg Med. 1995;13(6):857–61.
52. Alvi AR, Khan S, Niazi SK, Ghalam M, Bibi S. Acute mesenteric venous thrombosis: improved outcome with early diagnosis and prompt anticoagulation therapy. Int J Surg. 2009;7(3):210–3.
53. Golino A, Crawford EM, Gathe JC, Dekmezian RH. Recurrent small bowel infarction associated with antithrombin deficiency. Am J Gastroenterol. 1997;92(2):323–5.
54. Cangemi JR, Picco MF. Intestinal ischemia in the elderly. Gastroenterol Clin N Am. 2009;38:527–40.
55. Chang KC, Weng YM, Chen SY, Chang YC. Nephrotic syndrome complicated with acute mesenteric ischemia. Am J Emerg Med. 2011;29(2):243.e1–3.
56. Pignere et S, Baudron Lecame M, Chèdru Legros V, Choussy O, Babin E. Acute mesenteric ischemia and rhinopharyngeal carcinoma. Rev Laryngol Otol Rhinol (Bord). 2007;128(1-2):105–108 (French).
57. Yasuhara H. Acute mesenteric ischemia: the challenge of gastroenterology. Surg Today. 2005;35(3):185–95.
58. Wahlberg E, Olofsson P, Goldstone J. Acute intestinal ischemia. In: Wahlberg E, Olofsson P, Goldstone J, editors. Emergency vascular surgery—a practical guide. Berlin, Heidelberg: Springer; 2007. p. 65–74.
59. El Hennawy HM, Abdalla MF, El-Osta A, Bedair EM. Isolated ileocolic artery occlusion presented with segmental bowel infarction: a case report. Cases J. 2009. doi:10.1186/1757-1626-2-9153.
60. Doruti S, Lamont PM. Intestinal ischemia in the unconscious intensive care unit patient. Ann Roy Coll Surg Eng. 1992;74:356–9.
61. Mitsuyoshi A, Obama K, Shinkura N. Survival in nonocclusive mesenteric ischemia. A case report. Cases J. 2009. doi:10.1186/1757-1626-2-9153.
62. Malbranque S, Piercecchi-Marti MD, Thomas L, Barbay C, Courdier D, Bucher B, Ridarch A, Smadja D, Warrell DA.Fatal diffuse thrombotic microangiopathy after a bite by the “Fe-de-Lance” pit viper (Bothrops lanceolatus) of Martinique. Am J Trop Med Hyg. 2008;78(6):856–61.
63. Melis M, Fichera A, Ferguson MK. Bowel necrosis associated with early jejunal tube enteral feeding. Arch Surg. 2004;141:701-4.
64. Allaix ME, Krane MK, Zoccali M, Umanskiy K, Hurst R, Fichera A. Postoperative portomesenteric venous thrombosis: lessons learned from 1,069 consecutive laparoscopic colorectal resections. World J Surg. 2014;38:976–84.
65. Santana AC, Rodrigues AL, Mqueiros LC. Acute mesenteric ischemia following colonoscopy: report from Brazilian Amazon region. Trop Gastroenterol. 2009;30(3):155–7.
66. Schütz A, Eichinger W, Breuer M, Gansera B, Kemkes BM. Acute mesenteric ischemia after open heart surgery. Angiology. 1998;49(4):267–73.
67. Gupta PK, Natarajan B, Gupta H, Fang X, Fitzgibbon RJ Jr. Morbidity and mortality after bowel resection for acute mesenteric ischemia. Surgery. 2011;150(4):779–87.
68. Armalich F, Malfiatiessi MC, Ciria E, Quesada A, Codocero R, Herrero F, Garcia-Cerrada C, Montoya F, Vazquez JJ, Lopez-Collazo E, Montiel C. Association of cell-free plasma DNA with perioperative mortality in patients with suspected acute mesenteric ischemia. Clin Chim Acta. 2010;411(17-18):1269–74.
69. Acosta S, Nilsson T. Current status on plasma biomarkers for acute mesenteric ischemia. J Thromb Thrombolysis. 2012;33(4):355–61.
70. Matsumoto S, Sekine K, Funaoaka H, Yamazaki M, Shimizu M, Hayashida K, Kitano M. Diagnostic performance of plasma biomarkers in patients with acute intestinal ischaemia. Br J Surg. 2014;101(3):232–8.
71. Evennett NJ, Petrov MS, Mittal A, Windsor JA. Systematic review and pooled estimates for the diagnostic accuracy of serological markers for intestinal ischemia. World J Surg. 2009;33:1374–83.
72. Demir IE, Ceyhan GO, Friess H. Beyond lactate: is there a role for serum lactate measurement in diagnosing acute mesenteric ischemia? Dig Surg. 2012;29(3):226–35.
73. Jakob SM, Merasto-Minkinnen M, Tehunen JJ, Heino A, Alhava E, Takala J. Prevention of systemic hyperlactatemia during splanchic ischemia. Shock. 2000;14(2):123–7.
74. Hmoud B, Singal AK, Kamath PS. Mesenteric Venous Thrombosis. J Clin Exp Hepatol. 2014;4:257–63.
75. Chiu YH, Huang MK, How CK, Hsu TF, Chen JD, Chen CH, Yen DH, Huang CI. D-dimer in patients with suspected acute mesenteric ischemia. Am J Emerg Med. 2009;27(8):975–9.
76. Van den Heijjik TC, Aerts BAC, Teijink JA, Buurman WA, Luyer MDP. Challenges in diagnosing mesenteric ischemia. W J Gastroenterol. 2013;19(9):1338–41.
77. Oliva IB, Davarpanah AH, Rybicki FJ, et al. ACR appropriateness criteria: imaging of mesenteric ischemia. Abdom Imaging. 2013;38(4):714–9.
78. Cudnik MT, Darbha S, Jones J, Macedo J, Stockton SW, Hiendel BC. The diagnosis of acute mesenteric ischemia: a systematic review and meta-analysis. Acad Emerg Med. 2013;20:1087–100.
79. Yanar F, Ascaoglu O, Gok AFK, Sarici IS, Ozcinar B, Aksakal N, Aksoy M, Ozkurt E, Kurtoglu M. The management of mesenteric vein thrombosis: a single institution’s experience. Turk J Trauma Emerg Surg. 2013;19(3):223–8.
80. Schieda N, Fasih N, Shabana W. Triphasic CT in the diagnosis of acute mesenteric ischaemia. Eur Radiol. 2013;23(7):1891–900.
81. Yukilmaz A, Karahan OI, Senol S, Tuna IS, Akyildiz HY. Value of multislice computed tomography in the diagnosis of acute mesenteric ischemia. Eur J Radiol. 2011;80(2):297–302.
82. Furukawa A, Kanasaki S, Kono N, Wakamiya M, Tanka T, Takahashi M, Murata K. CT diagnosis of acute mesenteric ischemia from various causes. Am J Roentgenol. 2009;192(2):408–16.
83. McLeod R, Lindsay T, O’Malley M. Evidence based reviews in surgery group. Canadian Association of General Surgeons and American College of Surgeons evidence based reviews in surgery. 15. Biphasic CT with mesenteric CT angiography in the evaluation of acute mesenteric ischemia: initial experience. Can J Surg. 2005;48(6):491–3.
84. Barmase M, Kang M, Wig J, Kochhar R, Gupta R, Khandelwal N. Role of multidetector CT angiography in the evaluation of suspected mesenteric ischemia. Eur J Radiol. 2011;80(2):582–7.
85. Lee SS, Park SH. Computed tomography evaluation of gastrointestinal bleeding and acute mesenteric ischemia. Radiol Clin N Am. 2013;51(1):29–43.
86. Menke J. Diagnostic accuracy of multidetector CT in acute mesenteric ischemia: systematic review and meta-analysis. Radiology. 2010;256(1):93–101.
87. Kirkpatrick IDC, Kroeker MA, Greenberg HM. Biphasic CT with mesenteric CT angiography in the evaluation of acute mesenteric ischemia: initial experience. Radiology. 2003;229:91–8.
88. Lee MJ, Sperry JL, Rosengart MR. Evaluating for acute mesenteric ischemia in critically ill patients: diagnostic peritoneal lavage is associated with reduced operative intervention and mortality. J Trauma Acute Care Surg. 2014;77:441–7.
89. Anderson JL, Halperin JL, Albert N, et al. Management of patients with peripheral artery disease (Compilation of 2005
and 2011 ACCF/AHA Guideline Recommendations). A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(14):1555–70.

91. Acosta S, Bjorck M. Modern treatment of acute mesenteric ischaemia. Br J Surg. 2014;101:e100–8.

92. Woodhams R, Nishimaki H, Fujii K, et al. Usefulness of multidetector-row CT (MDCT) for the diagnosis of non-obstructive mesenteric ischaemia (NOMI): assessment of morphology and diameter of the superior mesenteric artery (SMA) on multi-planar reconstructed (MPR) images. Eur J Radiol. 2010;76:96–102.

93. Kazui T, Yamasaki M, Abe K, et al. Non-obstructive mesenteric ischemia: a potentially lethal complication after cardiovascular surgery: report of two cases. Ann Thorac Cardiovasc Surg. 2012;18(1):56–60.

94. Yanar H, Taviloglu K, Ertekin C, Ozcinar B, Yanar F, Gologlu R, Kurtoglu M. Planned second-look laparoscopy in the management of acute mesenteric ischemia. World J Gastroenterol. 2007;13(24):3350–3.

95. Tshomba Y, Coppi G, Marone EM, Bertoglio L, Kahlberg A, Müller RG, Haase N, Wetterslev J, Perner A. Effects of hydroxyethyl starch is not very helpful. Scand J Trauma Resusc Emerg Med. 2012;20(29):9936–41.

96. Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation of critically ill patients. Cochrane Database of Syst Rev. 2010. doi:10.1002/14651858.CD000567.pub6.

97. Perner A, Haase N, Guturomsen AB, et al. Hydroxyethyl starch 1300:42 versus Ringer’s acetate in severe sepsis. N Engl J Med. 2012;367(2):24–34.

98. Bobadilla JL. Mesenteric ischemia. Surg Clin N Am. 2013;93:165–40.

99. Sise MJ. Acute mesenteric ischemia. Surg Clin N Am. 2014;94:165–81.

100. Joosten A, Alexander B, Cannesson M. Defining goals of resuscitation in the critically ill patient. Crit Care Clin. 2015;31(1):113–32.

101. Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database of Syst Rev. 2010. doi:10.1002/14651858.CD004539.pub2.

102. Wils H, Mittal A, Haydock MD, van den Heever M, Devaud M, Windsor JA. A systematic review of goal directed fluid therapy. Rating of evidence for goals and monitoring methods. J Crit Care. 2014;29:204–209.

103. Bobadilla JL. Mesenteric ischemia. Surg Clin N Am. 2013;93:165–40.

104. Haase N, Müller R, Perner A. Debate on HES safety is important, but must be based on facts. Scand J Trauma Resusc Emerg Med. 2013;21:85.

105. Müller RG, Haase N, Wetterlsve J, Perner A. Effects of hydroxyethyl starch in subgroups of patients with severe sepsis: exploratory post hoc analyses of a randomised trial. Intensive Care Med. 2013;39(11):1963–71.

106. Klar E, Rahmanian PB, Bücke A, Hauenstein K, Jauch KW, Luther B. Acute mesenteric ischemia: a vascular emergency. Dtsch Arztebl Int. 2012;109(14):249–56.

107. Wong PF, Gilliam AD, Kumar S, Shenfine J, O’Dair GN, Leaper DJ. Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. Cochrane Database of Syst Rev. 2005. doi:10.1002/14651858.CD004539.pub2.

108. Kim BG, Ohm JY, Bae MN, Kim HN, Kim YJ, Chung MH, Park CS, Ihm SH, Kim HY. Successful percutaneous aspiration thrombectomy for acute mesenteric ischemia in a patient with atrial fibrillation despite optimal anticoagulation therapy. Can J Cardiol. 2013;29(10):1329.e5–7.

109. Schoenbaum SW, Pena C, Koenigsberg P, Katzen BT. Superior mesenteric artery embolism: treatment with intra arterial urokinase. JVIR. 1992;3:485–90.

110. Simó G, Echenagusia AJ, Camuñez F, Turégano F, Cabrera A, Urbano J. Superior mesenteric arterial embolism: local fibrinolytic treatment with urokinase. Radiology. 1997;204:775–9.

111. Jia Z, Jiang G, Tian F, Zhao J, Li S, Wang K, Wang Y, Jiang L, Wang W. Early endovascular treatment of superior mesenteric occlusion secondary to thromboemboli. Eur J Vasc Endovasc Surg. 2014;47(2):196–203.

112. Erdogan E, Turfan M, Akkaya M, Bacaksız A, Tasal A, Ergelen M, Goktekin O. Successful recanalization of acute superior mesenteric artery ischemia with balloon angioplasty and aspiration embolectomy. Eur Geriatr Med. 2013;4:350–1.

113. Blauw JTM, Meerwaldt R, Brasse-Kreizer M, Kolkman JJ, Gerrits D, Geelkerken RH. Retrograde open mesenteric stenting for acute mesenteric ischemia. J Vasc Surg. 2014;60:726–34.

114. Beaulieu RJ, Armaoutakis KD, Abularrage CJ, Efron DT, Schneider E, Black JD III. Comparison of open and endovascular treatment of acute mesenteric ischemia. J Vasc Surg. 2014;59:159–64.

115. Yang S, Wu X, Li J. Transcatheter thrombolyis centered stepwise management strategy for acute superior mesenteric venous thrombosis. Int J Surg. 2014;12:442–51.

116. Di Minno MND, Milone F, Milone M, Iaccarino V, Venetucci P, Lupoli R, Sosa Fernandez LM, Di Minno G. Endovascular thrombolysis in acute mesenteric vein thrombosis: a 3-year follow-up with the rate of short and long-term sequelae in 32 patients. Thrombosis Res. 2010;126:295–298.

117. Joh J-H, Kim D-I. Mesenteric and portal vein thrombosis: treated with early initiation of anticoagulation. Eur J Vasc Endovasc Surg. 2005;29:204–8.

118. Gong JF, Zhu WM, Xu XJ, Li N, Li JS. Damage control surgery for acute mesenteric ischemia. Zhonghua Wei Chang Wai Ke Za Zhi. 2010;13(1):22–5 (Chinese).

119. Freeman AJ, Graham JC. Damage control surgery and angiography in cases of acute mesenteric ischaemia. ANZ J Surg. 2005;75(5):308–14.

120. Kaminsky O, Yampolski I, Aranovich D, Gnessin E, Greif F. Does a second-look operation improve survival in patients with peritonitis due to acute mesenteric ischemia? A five-year retrospective experience. World J Surg. 2005;29(5):645–8.

121. Weber DG, Bendinelli C, Balogh ZJ. Damage control surgery for abdominal emergencies. Br J Surg. 2014;101(1):e109–118.

122. Accorsi S. Surgical management of peritonitis secondary to acute superior mesenteric artery occlusion. World J Gastroenterol. 2014;20(29):9936–41.

123. Perez D, Wildi S, Clavien P-A. The use of an abdominal vacuum-dressing system in the management of abdominal wound complications. Adv Surg. 2007;41:121–31.

124. Roberts DJ, Zygun DA, Grendar J, Ball CG, Robertson HL, Ouellet J-F, Cheatham ML, Kirkpatrick AW. Negative-pressure wound therapy for critically ill adults with open abdominal wounds: a systematic review. J Trauma Acute Care Surg. 2012;73(3):629–39.

125. Martin N, Sarani B. Management of the open abdomen in adults. Uptodate. 2015. http://www.uptodate.com/contents/management-of-the-open-abdomen-in-adults. Accessed 3 July 2015.

126. Meng X, Liu L, Jiang H. Indications and procedures for second-look surgery in acute mesenteric ischemia. Surg Today. 2010;40(8):700–5.

127. Wyers MC. Acute mesenteric ischemia: diagnostic approach and surgical treatment. Semin Vasc Surg. 2010;23(1):9–20.

128. Khiprun AJ, Priamikov A, Shurygin SN, Mironkov AB, Petrenko NV, Grigor’eva SG, Latonov VV, Abashin MV, Izvekov AA. The possibilities of laser Doppler flowmetry for the estimation of the intestine resection volume by the acute
mesenteric ischemia. Khirurgiia (Mosk). 2012;(10):40–44 (Russian).

129. Käser SA, Glauser PM, Maurer CA. Venous small bowel infarction: intraoperative laser Doppler flowmetry discriminates critical blood supply and spares bowel length. Case Rep Med. 2012. doi:10.1155/2012/195926.

130. Herbert GS, Steele SR. Acute and chronic mesenteric ischemia. Surg Clin N Am. 2007;87:1115–34.

131. Yamamoto M, Orihashi K, Nishimori H, Wariishi S, Fukutomi T, Kondo N, Kihara K, Sato T, Sasaguri S. Indocyanine green angiography for intra-operative assessment in vascular surgery. Eur J Vasc Endovasc Surg. 2012;43:426–32.

132. McKinsey JF, Gewertz BL. Acute mesenteric ischemia. Surg Clin N Am. 1997;77(2):307–18.

133. Messing B, Crenn P, Beau P, Boutron-Ruault MC, Rambaud JC, Matuchansky C. Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenterology. 1999;117(5):1043–50.

134. Du Toit A. Nutritional management of a complicated surgical patient by means of fistuloclysis. S Afr J Clin Nutr. 2014;27(4):230–6.

135. Garofalo M, Borioni R, Nardi P, Turani F, Bertoldo F, Forlani S, Pellegrino A, Chiariello L. Early diagnosis of acute mesenteric ischemia after cardiopulmonary bypass. J Cardiovasc Surg (Torino). 2002;43(4):455–9.

136. Unalp HR, Atahan K, Kamer E, Yaşlı H, Tarcan E, Onal MA. Prognostic factors for hospital mortality in patients with acute mesenteric ischemia who undergo intestinal resection due to necrosis. Ulus Travma Acil Cerrahi Derg. 2010;16(1):63–70 (Turkish).

137. Macarone Palmieri R, Massi G, Bertolini R, Caselli A, Sciaccà P, Marinozzi S, Berghella G, Negozi E, Brancadoro G. Prognostic factors in acute mesenteric ischemia. Experience of 64 cases. G Chir. 1989;10(10):562–6 (Italian).

138. Szabóné Révész E. Acute mesenteric ischemia: analysis of cases over a ten-years period (2001–2010). Orv Hetil. 2012;153(36):1424–32 (Hungarian).

139. Alhan E, Usta A, Çekiç A, Saglam K, Türkylmaz S, Cinel A. A study on 107 patients with acute mesenteric ischemia over 30 years. Int J Surg. 2012;10(9):510–3.

140. Lobo Martinez E, Carvajosa E, Sacco O, Martinez Molina E. Embolectomy in mesenteric ischemia. Rev Esp Enferm Dig. 1993;83:351–4.

141. National Institute for Health and Care Excellence. Preventing vascular events. Secondary prevention of cardiovascular disease in patients with peripheral arterial disease. 2015. http://pathways.nice.org.uk/pathways/lower-limb-peripheral-arterial-disease#content=view-node%3Anodes-preventing-vascular-events. Accessed 1 June 2015.